Table 3 Summary of the most frequent treatment-emergenta adverse events (n=38)

From: Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer

 

All grades, n (%)

Grade 1, n (%)

Grade 2, n (%)

Grade 3, n (%)

Grade 4

Fatigue

14 (37)

8 (21)

9 (11)

2 (5)

Nausea

11 (29)

3 (8)

4 (11)

4 (11)

Anorexia

9 (24)

5 (13)

3 (8)

1 (3)

Abdominal pain

8 (21)

3 (8)

1 (3)

4 (11)

Diarrhoea

6 (16)

3 (8)

3 (8)

Dyspnea

6 (16)

1 (3)

1 (3)

4 (11)

Peripheral oedema

6 (16)

3 (8)

2 (5)

1 (3)

Vomiting

6 (16)

2 (5)

1 (3)

3 (8)

Insomnia

5 (13)

3 (8)

2 (5)

Pyrexia

5 (13)

3 (8)

2 (5)

Ascites

4 (11)

1 (3)

1 (3)

2 (5)

Back pain

4 (11)

2 (5)

2 (5)

Constipation

4 (11)

2 (5)

1 (3)

1 (3)

Cough

4 (11)

1 (3)

3 (8)

  1. aRegardless of study drug relationship.